

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1.-18. Canceled

19. (Presently Amended) A method of stimulating an immune response, said method comprising administering a composition comprising ~~... (a) an isolated polypeptide comprising SEQ ID NO: 140; (b) an isolated polypeptide comprising an immunogenic portion of SEQ ID NO: 140; and (c) a~~ an isolated polypeptide having at least 95% identity to the entirety of SEQ ID NO: 140, and thereby stimulating an immune response specific for ~~a *Chlamydia* CT875 protein~~ the polypeptide of SEQ ID NO: 140.

20. (Previously Presented) The method of claim 19, wherein the composition further comprises a physiologically acceptable carrier.

21. (Previously Presented) The method of claim 19, wherein the composition further comprises an adjuvant.

22. (Previously Presented) The method of claim 21, wherein the adjuvant induces an immune response predominantly of the Th1 type.

23. (Previously Presented) The method of claim 22, wherein the adjuvant is selected from the group consisting of monophosphoryl lipid A, 3-de-O-acylated monophosphoryl lipid A, CpG-containing oligonucleotides, saponins, QS21, and combinations thereof.

24. (Previously Presented) The method of claim 21, wherein the adjuvant is an aminoalkyl glucosaminide 4-phosphate.

25. (Previously Presented) The method of claim 24, wherein the aminoalkyl glucosaminide 4-phosphate is RC-529.

26. (Previously Presented) The method of claim 19, wherein the composition comprises the polypeptide of SEQ ID NO: 140.